TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten® for the Treatment of Intradialytic Hypotension

TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten® for the Treatment of Intradialytic Hypotension

Phase II clinical trials in patients undergoing hemodialysis to be initiated in Q4, 2018 NEWARK, Delaware, May 29, 2018 /PRNewswire/ — TrioxBio Inc., a clinical-stage biopharmaceutical company specializing in the development of drugs to treat diseases and medical conditions related to the